Breast Cancer: Open Trials


ABCSG 22R-QoL

A questionnaire investigating long-term quality of life (QoL) outcome including sexual health and fertility concerns based survey among breast cancer patients registered in ABCSG 22R.



ABCSG 45

A prospective, open, randomized, phase II study of carboplatin/ olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive homologous recombination deficiency (HRD) status



ABCSG 47 / IMpassion030

A phase III, multicenter, randomized, open-label study comparing atezolizumab (anti PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer

ABCSG 49 / POLAR

A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer

Palbociclib for HR positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR)  



ABCSG 50/BRCA-P

A randomized, double-blind, placebo-controlled, multi-center, international phase 3 study to determine the preventive effect of denosumab on breast cancer in women carrying a BRCA1 germline mutation.



ABCSG 51/ AURORA

Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer